Early costs and complications of first-line low-grade glioma treatment using a large national database: Limitations and future perspectives

IntroductionDiffuse Low-grade gliomas (DLGG, WHO Grade II) are a heterogenous group of tumors comprising 13–16% of glial tumors. While maximal safe resection is endorsed as the best approach to DLGG, compared to more conservative interventions like stereotactic biopsy, the added costs and risks have...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Kyle Tuohy, Djibril M. Ba, Debarati Bhanja, Douglas Leslie, Guodong Liu, Alireza Mansouri
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2023-02-01
Saila:	Frontiers in Surgery
Gaiak:	low-grade glioma (WHO grade II) cost resection stereotactic biopsy adverse events—complications MarketScan database
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fsurg.2023.1001741/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!